Abiomed, a cardiac support device manufacturer, has issued a field action for its 14Fr Low Profile Introducer kits due to the risk of thrombus (blood clot) formation during prolonged catheterisation, according to a notice posted on the US Food and Drug Administration (FDA) website. The action affects devices used in ventricular assist device (VAD) implantation and other cardiac support procedures.
Key takeaways
- Abiomed 14Fr Low Profile Introducer kits pose a thrombus formation risk with prolonged use
- The FDA has been notified; healthcare facilities should verify affected inventory
- Clinicians should heighten surveillance for thromboembolic complications in recent VAD patients
Catheter-Associated Thrombosis: Clinical Risk Window
Thrombus formation risk increases with prolonged device dwelling time in cardiovascular procedures
Clinical context based on catheter-related thromboembolism literature | Georgian Medical Journal News
Field Action and Clinical Implications
The FDA notice indicates that prolonged use of the Abiomed 14Fr Low Profile Introducer may increase the risk of thrombus formation. Introducer kits are critical components in VAD implantation and other percutaneous cardiac interventions. Healthcare facilities using these devices should verify their inventory and assess whether affected units remain in stock or have been used in recent procedures.
Clinicians implanting or managing patients with recently placed Abiomed VADs should maintain heightened clinical vigilance for signs of thromboembolism, including unexplained fever, device thrombosis indicators on monitoring, or systemic embolic phenomena. This recommendation aligns with best practices in clinical management of ventricular assist device patients.
Regulatory and Safety Context
Device field actions issued through the FDA represent serious safety concerns that warrant immediate attention from healthcare providers and facilities. Catheter-related thrombosis is a well-documented complication of cardiac support devices, and any design or manufacturing issue that elevates this risk requires prompt communication to the clinical community. The FDA’s medical device division continues to monitor such risks as part of post-market surveillance.
Healthcare facilities should report any adverse events associated with these introducers to both Abiomed and the FDA through the MedWatch safety reporting system.
Recommended Actions for Healthcare Providers
Clinical teams should conduct an immediate audit of their inventory to identify affected 14Fr Low Profile Introducer kits and quarantine them pending further guidance from Abiomed. For patients who have recently undergone VAD implantation or other procedures using these introducers, close anticoagulation management and clinical monitoring for thrombotic events are advisable. Clinicians should document baseline coagulation parameters and maintain heightened vigilance during the post-procedure period. Additional guidance on device safety and quality assurance is available through institutional biomedical engineering and clinical risk management teams.
Prolonged use of the Abiomed 14Fr Low Profile Introducer may lead to thrombus formation, prompting the manufacturer and FDA to issue a safety field action.
— US Food and Drug Administration, Medical Device Safety Alert (2026)
What this means
Frequently asked questions
What is an introducer kit, and why is it used?
An introducer kit is a percutaneous vascular access device used to place larger catheters or devices (such as VADs) into blood vessels. The 14Fr (14 French, approximately 4.7 mm diameter) low-profile design allows clinicians to implant support devices with minimal vascular trauma while maintaining vessel patency during and after the procedure.
Why does prolonged use increase thrombosis risk?
Foreign material in contact with blood activates the coagulation cascade and platelets, initiating thrombus formation. Prolonged dwell time of the introducer in the vascular system allows time for fibrin deposition and platelet aggregation, increasing the risk of clinically significant clot formation that may embolise or occlude the device.
What should I do if I have had a recent VAD implant?
Contact your VAD clinic or implanting facility to confirm the brand and device type used. Maintain all anticoagulation medications as prescribed, attend scheduled follow-up appointments, and report any new symptoms (fever, reduced device function, signs of stroke) to your clinical team immediately. Do not discontinue anticoagulation without medical guidance.
Healthcare systems and clinicians should treat this field action as a priority communication, ensuring that all staff involved in VAD implantation, management, and post-operative care are informed. As the World Health Organization emphasises, effective communication of device safety alerts is essential to maintaining patient safety in advanced cardiac care.
Source: Catheter Introducer Kit Recall: Abiomed Removes 14Fr Low Profile Introducer Kits, US Food and Drug Administration
Was this article helpful?
Related Coverage
